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keletal Muscle-Derived
tem Cell Transplantation
ngiogenesis Is Required for
mproved Left Ventricular Function*
. Kirk Hammond, MD
an Diego, California
n 2001, reports in animal models of acute myocardial
nfarction (MI) indicated that that cell-based therapy could
e used to regenerate cardiac myocytes and thereby improve
ardiac function (1). The delivery of bone marrow-derived
ells, endothelial progenitor cells, embryonic or mesenchy-
al stem cells, and skeletal muscle-derived stem cells, to
ention a few, were associated with favorable effects on left
entricular (LV) function and remodeling in a variety of
reclinical studies (1–3), although questions regarding the
mportance of cardiac myocyte regeneration as the mecha-
ism for improvement in LV function have been raised
4,5). The general approaches and challenges of cell-based
pproaches to facilitate cardiac repair and the results of
reclinical and clinical studies were presented recently in
xcellent reviews (6–8).
See page 1677
Initial uncontrolled clinical trials of bone marrow-derived
ell therapy in acute MI showed consistent small increases
n LV ejection fraction (LVEF) (9), but subsequent ran-
omized controlled clinical trials showed variable results
10–14). For example, the BOOST (Bone Marrow Trans-
er to Enhance ST-Elevation Infarct Regeneration) trial
howed increases in LVEF 6 months after treatment (9)
hich were not still present 12 months later (10). The
STAMI (Autologous Stem Cell Transplantation in Acute
yocardial Infarction) trial found a decrease in LVEF in
he treatment group (11), whereas a study by Janssen et al.
12) found no change in LVEF, although infarct size was
educed and regional function increased by treatment,
espite absence of changes in regional myocardial perfusion.
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From the Department of Medicine, University of California at San Diego, and
eteran’s Administration San Diego Healthcare System, San Diego, California. Dr.l
ammond is supported by National Institutes of Health grants 5P01HL066941 and
L081741 and a merit grant from the Department of Veteran’s Affairs.he REPAIR-AMI (Reinfusion of Enriched Progenitor
ells and Infarct Remodeling in Acute Myocardial Infarc-
ion) trial investigators found that LVEF increased more in
reated patients than in control subjects. Although the
hange was small (5.5% vs. 3.0%), clinical events indicating
ecurrent ischemia were reduced 12 months after treatment
13). A randomized controlled clinical study that examined
he usefulness of granulocyte colony-stimulating factor to
obilize bone marrow cells in the setting of acute MI failed
o show a favorable effect on LVEF (14).
Recently, a randomized controlled clinical trial of cell-
ased therapy for the treatment of chronic ischemia was
eported (15). Patients were enrolled 3 months after acute
I if they had an open vessel perfusing a dysfunctional
egion of myocardium. Only one-third of patients had class
or 4 congestive heart failure (CHF) symptoms, but
retreatment LVEFs ranged from 30% to 43%. Three
onths after intracoronary infusion of bone marrow-
erived cells, patients had an increase in mean LVEF from
1% to 43%, which was better than the patients who
eceived no cell therapy or cell therapy derived from circu-
ating blood (p  0.001) (15). A subsequent registry report
f 121 patients (including those just mentioned) with
hronic myocardial ischemia who received intracoronary
nfusion of bone marrow-derived mononuclear progenitor
ells showed a reduction in serum natriuretic peptide levels
9 months later. Patients that received bone marrow cells
ith higher (vs. lower) functional capacity showed increased
urvival (16). These data support the initiation of a larger
andomized controlled clinical trial of cell-based therapy for
atients with frank CHF with evaluation for sustained
enefits of therapy.
The mechanism for beneficial cardiac effects remains
ncertain. Cardiac regeneration is a possibility (1,3), but it
as been difficult to confirm (4,5). In some clinical trials, LV
unctional improvement has been associated with an in-
reased regional myocardial perfusion, suggesting that cell-
ased therapy may evoke myocardial angiogenesis (17–19).
ut how robust are data showing that the mechanism for
eneficial effects is angiogenesis?
In the current issue of the Journal, Payne et al. (20),
njected skeletal muscle-derived stem cells (MDSC) in the
earts of animals directly after coronary occlusion. Saline
njection was compared with 3 types of MDSC injection:
DSC alone and MDSC engineered to express vascular
ndothelial growth factor (VEGF) or soluble Flt1 (a VEGF
ntagonist). Cardiac function and LV remodeling were then
erially evaluated by echocardiography, and angiogenesis
as assessed using histologic methods. Injection of MDSC,
hether engineered to express VEGF or not, was associated
ith increased LV function, reduced adverse LV remodel-
ng, and increased angiogenesis. Furthermore, animals that
eceived MDSC engineered to secrete Flt1 did not show
eneficial effects even though cell engraftment was estab-
ished (20). In vitro studies showed that MDSC released
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Editorial Comment October 23, 2007:1685–7EGF in vitro when stimulated with hypoxia and cyclic
tretch.
This study indicates that angiogenesis was required for
he favorable effects associated with MDSC transplantation
n a clinically relevant animal model of cardiac dysfunction.
y inference, many of the favorable effects seen in clinical
rials may reflect angiogenesis rather than cardiac myocyte
egeneration. This in itself, while not a new concept, has not
reviously been so clearly demonstrated. Furthermore, be-
ause angiogenesis associated with cell-based therapy may
e due to direct incorporation of progenitor cells into new
essels, or associated with chemoattraction and cytokines,
he current studies focus on the paracrine release of VEGF
s a dominant mechanism. Payne et al. have performed a
onvincing a priori test of the role of angiogenesis in
ell-based therapy for myocardial dysfunction.
There are several issues to consider regarding clinical
pplication of this approach. 1) Arrhythmia: injection of
DSC into failing human hearts has been associated with
n increased incidence of subsequent sustained ventricular
achycardia (VT) (21). Owing to low expression of
onnexin-43 gap junction protein, engrafted MDSCs do
ot exhibit optimal electrophysiological integration, which
ay be the mechanism for arrythmogenesis (21). Injection
f cells into viable hibernating rather than infarcted regions
ay reduce the incidence of VT (7). 2) Brief engraftment:
reclinical studies indicate that engrafted cells remain in the
eart very briefly, a few days at most (7). If paracrine-related
ngiogenesis is the mechanism for improved LV function,
ustained secretion of angiogenic proteins may be required.
lthough the authors cite a report indicating that engrafted
DSCs secrete VEGF for 12 weeks (22), brief-duration
ngraftment is a widely recognized shortcoming of the
pproach (6,7). 3) Delayed treatment: the preparation of
utologous MDSCs will make immediate treatment for
I impossible. Logically, early intervention would be
xpected to yield better results, even when the infarct-
elated artery is opened by percutaneous coronary inter-
ention, because the targeted area is the infarct border
egion that, owing to dysynergic contraction, suffers from
ustained ischemia and is thereby prone to adverse
emodeling (23).
mplications. The principal finding of Payne et al. (20) is
hat the beneficial effects of MDSC injection result from
aracrine secretion of an angiogenic growth factor. Is cell
ransplantation the optimal means to obtain paracrine-
elated secretion of angiogenic factors? The use of virus
ectors encoding VEGF could be injected immediately after
I and could elaborate VEGF for sustained periods,
ithout presenting the heart with a heterogeneous electro-
hysiological substrate, thereby circumventing 3 of the
roblems associated with MDSC transplantation. Although
ardiovascular gene transfer is bedeviled with its own
truggles, data from preclinical models of acute and chronic
yocardial ischemia demonstrated favorable effects on LVunction (24) similar to those described with cell-based
herapy.
Payne et al. (20) provides a simple and elegant study
ndicating that transplanted MDSCs provide favorable ef-
ects through paracrine release of VEGF and subsequent
ngiogenesis. If this is the sole mechanism of benefit,
lements likely to improve results in clinical trials may
nclude identification of the cell and delivery method that
rovides persistent and efficient cardiac engraftment. Engi-
eering these cells to express angiogenic factors (alone or in
ombination) whose expression is governed by biological
ignals (ischemia/hypoxia) may provide additional advan-
ages. That cell-based treatment of acute MI advanced from
he first preclinical observation (1) to completion of the first
andomized clinical trial (9) in 3 years is impressive but
xplains, perhaps, why there is so much potential for
mprovement.
eprint requests and coorespondence: Dr. H. Kirk Hammond,
A San Diego Healthcare System (111A), 3350 La Jolla Village
rive, San Diego, California 92161. E-mail: khammond@ucsd.edu.
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